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We have shown that lymphocytes of breast cancer patients are, on
average, more sensitive than those of normal healthy controls to
the induction of chromosome damage by ionizing radiation. This
was true for cells irradiated in either the G2 or G0 phases of the cell
cycle (Scott et al, 1994, 1998, 1999). The G2 assay involved the
analysis of metaphase cells for structural aberrations whereas, in
the G0 assay, chromosome damage was measured as the induction
of micronuclei (MN). Our G2 observations have now been
confirmed in three independent studies in different laboratories
(Parshad et al, 1996; Patel et al, 1997; Terzoudi et al, 2000). 
Using the G2 assay on 105 normal individuals we found a
skewed distribution of induced aberration yields, with 5–10% of
donors being sensitive outliers. This proportion was much higher
(42%) among 135 breast cancer patients (Scott et al, 1999). With
the MN assay we found that 27% (35 of 130) of patients were of
elevated sensitivity, compared with 10% (7 of 68) of normals.
When we performed both assays on the same 80 patients we found
no evidence of a correlation between aberration yields in the G2
assay and MN yields in the G0 assay (Scott et al, 1999) suggesting
that the cellular defects leading to enhanced sensitivity are
different in these cell cycle stages. 
We have recently shown that the degree of sensitivity in the G2
assay is an inherited characteristic in the families of patients with
breast cancer and could be attributed to the segregation of one or
two genes in each family (Roberts et al, 1999; Scott et al, 2000).
We also have preliminary evidence that elevated sensitivity in the
G0/MN assay is a heritable trait in first-degree relatives of breast
cancer patients (Burrill et al, 2000). 
These observations in breast cancer patients and their families
have led us to suggest that such enhanced chromosomal radio-
sensitivity may be a marker of cancer-predisposing genes. Support
for this hypothesis comes from the demonstration that many
inherited cancer-prone conditions (e.g. ataxia-telangiectasia,
Li–Fraumeni syndrome, hereditary retinoblastoma) exhibit
evidence of this type of elevated radiosensitivity (reviewed in
Scott et al, 1999) but, in contrast to the situation in our breast
cancer studies, the gene defects responsible for cancer predisposi-
tion in these rare syndromes are generally strongly expressed
(highly penetrant). We propose that the defects leading to the
enhanced radiosensitivity that we have seen in our studies are
associated with a lesser risk of cancer and therefore do not lead to
a strong family history (low-penetrance genes). There is good
epidemiological evidence that the inherited risk of breast cancer is
greater than can be accounted for by mutations in the highly pene-
trant genes BRCA1,  BRCA2 and  TP53 (Teare et al, 1994;
Lichtenstein et al, 2000; Peto and Mack, 2000). 
There is also indirect evidence for the existence of low-
penetrance, inherited, predisposing factors for cancers other than
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Albright et al, 1988) and head and neck cancers. For the latter
group, Foulkes et al (1995) found, in a case-control study, that
even when allowing for the known environmental risk-factors such
as alcohol and tobacco consumption, cancer in a first-degree rela-
tive was a significant independent risk-factor. 
In the present study, we have investigated the chromosomal
radiosensitivity of head and neck cancer patients and normal
healthy controls, using both the G2 and G0 assays. Because it has
been suggested that genetic factors may be particularly important
in young patients with head and neck cancers, where there will be
a reduced impact of cumulative environmental factors (Son and
Kapp, 1985), our selection of cancer cases has been biased in
favour of such early-onset patients. Our sample of patients also
included a small number of cases who had shown adverse reac-
tions to radiotherapy, because we have previously shown that the
average radiosensitivity of breast cancer patients of this type may
be greater than that of normally-reacting patients, depending upon
the nature of the reactions and the type of assay (Barber et al,
2000). 
MATERIALS AND METHODS 
Patients and normal controls 
Individuals tested with the G2 and/or the G0 assay comprised 4
groups: 
1. Healthy subjects (normals), mainly from within the staff of
this Institute but including a small number of spouses of
patients 
2. Head and neck cancer patients at the Christie Hospital before
they received radiotherapy (pre-therapy cases) 
3. Patients after radiotherapy (9 months to 10 years post-therapy,
mean 5.7, SD 2.5 years). These will be referred to as post-
therapy cases 
4. A small group of patients after radiotherapy (2–5 years, mean
3.7, SD 1.2) for whom the treating clinician identified radia-
tion necrosis as a late complication following a standard radio-
therapy schedule. These are designated ‘highly radiosensitive’
(HR) patients according to the nomenclature of Burnet et al
(1998). 
The majority (36 of 50) of the patients had tumours of the larynx,
other sites being mouth, tongue, tonsil, oral cavity and oropharynx.
The distribution of sites was not significantly different between
patients groups 2–4. Over the period of this study the proportion of
early onset (<45 years) laryngeal cancer cases admitted to this
hospital was 3.3%, whereas in our sample the proportion was 21%
(11 of 52), indicating our preferential selection of younger cases. 
Details of tobacco and alcohol consumption were obtained from
those patients who volunteered this information, but not from
normals. Table 1 shows the characteristics of the various patient
groups. Permission for the study was obtained from the local
Ethics Committee. 
The G2assay 
Full details are given in Scott et al (1999). Briefly, whole-blood
cultures were set up in pre-warmed (37˚C) and pre-gassed (5%
CO2, 95% air) medium. One hour later, lymphocytes were stimu-
lated with phytohaemagglutinin (PHA) and cultured for 70 h, at
which time the culture medium was replaced, without centri-
fugation, with fresh medium. Cells were irradiated (or mock-
irradiated) at 72 h with 0.5 Gy 300 Kv X-rays, colcemid was
added 30 min later and at 90 min after irradiation culture vessels
were plunged into ice chippings. Subsequent centrifugation, hypo-
tonic treatment and fixation was carried out at 4˚C. From 1 h before
irradiation to the time of harvesting, cultures were kept at 37˚C.
Metaphase preparations were made with standard procedures
and Giemsa stained. Slides were randomized and coded for
analysis and 50–100 metaphases were scored from both irradiated
and control samples. The frequency of aberrations in control
samples was subtracted from that in irradiated samples to give the
induced yield. The majority of aberrations were chromatid breaks
which were misaligned with respect to the intact sister chromatid
or, if aligned, had an achromatic region of greater than the width of
the chromatid. Smaller achromatic lesions (gaps) and occasional
radiotherapy-induced chromosome-type aberrations in patients
were ignored. 
The G0 micronucleus assay 
These experiments were performed before we had standardized
our MN assay (Scott et al, 1999) so the procedures differ in several
respects from those used in our studies of breast cancer patients. 
Heparinized whole blood was kept overnight (16–24 h) at room
temperature, then 0.5 ml aliquots were added to 4.5 ml of culture
medium which comprised 82% RPMI 1640 (Flow Laboratories,
Ashby de la Zouche, UK), 15% fetal calf serum (FCS) (Gibco
BRL, Lewes, UK), 1% L-glutamine (Gibco BRL) and 2% of a
mixture of penicillin and steptomycin (both at 5000 units ml–1).
The medium was in T-25 flasks (Corning Costar, High Wycome,
UK) and was pre-warmed (37˚C) and pre-gassed (5% CO2, 95%
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Table 1 Details of participants 
Series Group n M/F Mean age at Mean age at Tobacco: mean  Alcohol: mean units
assay (SD) diagnosis (SD) pack-years (SD) per week (SD)
G2 Normals 27 10/17 48.6 (17.2) – – – 
Pre-therapy 16 12/4 60.3 (12.2) * 24.8 (21.0) n = 10 16.2 (12.4) n = 9 
Post-therapy 20 16/4 52.2 (13.6) 46.6 (11.6) 17.8 (18.0) n = 18 23.4 (29.6) n = 10 
HR 6 4/2 62.7 (5.1) 59.3 (6.3) 20.7 (13.3) n = 3 34.0 (31.1) n = 2 
G0 Normals 31 14/17 48.5 (17.0) – – – 
Pre-therapy 22 16/6 61.0 (13.3) * 22.2 (18.2) n = 14 15.7 (11.2) n = 13 
Post-therapy 23 18/5 54.7 (14.7) 49.0 (12.7) 20.1 (18.8) n = 21 27.8 (28.7) n = 14 
HR 4 2/2 62.0 (4.2) 58.5 (5.4) 28.0 (5.7) n = 2 12.0 n = 1 
* Pre-therapy cases assayed shortly after diagnosis778 R Papworth et al 
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air). One hour after setting up the cultures they were irradiated (or
mock-irradiated) with 3.0 Gy 137Cs gamma rays at 3.3 Gy min–1
and returned to the incubator for 1 h, at which time PHA was
added at a final concentration of 1.0 mg ml–1. At 24 h after PHA
stimulation, 3 ml of culture medium was pipetted from each
culture flask and replaced with fresh, pre-warmed and pre-gassed
medium, then cytochalasin-B was added at a final concentration of
6 mg ml–1 to enable the identification of post-mitotic cells as binu-
cleates (Fenech and Morley, 1985). 
At 72 h after stimulation, ‘clean’ cytospin preparations were
made, first by separating the lymphocytes from other cells (mainly
erythrocytes) in the culture medium by layering the contents of each
flask onto 5 ml of Lymphoprep (Nycomed, Amersham, UK) in a
12.5 ml centrifuge tube and centrifuging at 1100 rpm for 30 min.
Then, an aliquot of the lymphocyte-rich buffy coat was removed
with a small pipette, suspended in 5 ml of PBS and centrifuged at
1500 rpm for 5 min. The latter procedure was repeated and cells
were resuspended in 1 ml of PBS. Aliquots of 100–200 ml were then
pipetted into cytofunnel chambers and spun onto clean microscope
slides by cytocentrifugation for 2 min at 1000 rpm. Cells were fixed
in 90% methanol, dried, stained with 10% Giemsa for 10 min, rinsed
in distilled water, dried and mounted. 
Slides were randomized and coded and a minimum of 100 binu-
cleate cells was scored for MN from both irradiated and control
samples. 
The principal differences between this protocol and that which
has now become our standard procedure (Scott et al, 1999) are:
a radiation dose of 3 Gy (3.5 Gy in our standard assay), a delay of
1 h between irradiation and addition of PHA (cf. 6 h), fixation at
72 h after stimulation (cf. 90 h) and cell preparation by cytocentri-
fugation (cf. conventional harvesting with a short hypotonic treat-
ment). Cells were scored using similar criteria for both assays but
by different microscopists. 
Statistical methods 
Assay variability was assessed using standard one-way analysis of
variance. Aberration yields were compared using Mann–Whitney
U-tests, supplemented with Kruskall–Wallis tests where there
were more than two groups being compared. Proportions of sensi-
tive cases were compared using Fisher’s exact tests. Spearman’s
rank correlations were used to look at associations between
aberration yields and age. A significance level of 0.05 was used
throughout. 
RESULTS 
A total of 69 individuals were tested with the G2 assay, 80 with the
G0 assay (Table 1) and 64 with both (see Figure 5). When both
assays were used, this was with the same blood sample. 
The G2 assay 
The mean spontaneous yield of aberrations in the various patient
groups was slightly, but not significantly, above the level of
1.2 ± 1.5 per 100 cells in normal donors. 
To assess assay reproducibility, six normal donors were tested
on two (four donors) or three (two donors) occasions. The intra-
individual coefficient of variation (CV) for radiation-induced
aberration yields, which is a measure of assay error, was 7.3%,
very similar to the value of 7.0% which was our previous estimate
from repeat assays on 28 normal donors (Scott et al, 1999). 
The mean yield of induced aberrations in the 27 normals tested
in this study, was 117.7 ± 14.5 per 100 cells (Table 2), which is
higher than that from our earlier investigation of 105 normals
(97 ± 15, Scott et al, 1999). This is likely to be because the samples
from the two studies were scored by different microscopists and
probably reflects differences in the inclusion of small gaps in the
scores (see above). Although the mean yield in the 42 patients was
higher than normals, for none of the three patient subgroups (pre-
therapy, post-therapy or highly-radiosensitive) was this increase
statistically significant (Table 2, Figure 1). The highest yields were
seen in the post-therapy patients (127.0 ± 19.7) but this level was
not significantly (P = 0.13) above that in the pre-therapy group
(117.3 ± 14.4). There was no indication that the scores for the six
highly-radiosensitive (HR) patients were higher than those of the
20 post-therapy cases with normal reactions to radiotherapy. 
A method of comparing different groups of individuals, other
than simply using mean values, is to chose a cutoff value between
a normal and a sensitive response for healthy donors and to
compare this proportion of sensitive cases with the proportion of
patients whose yields are above the cutoff value (Table 2, Figure 1).
Previously, we have chosen the 90th percentile as the cutoff 
(Scott et al, 1999). Using this criterion, the cutoff value in the
present study was 135 aberrations per 100 cells. This actually gave
Table 2 Yields of induced G2 aberrations or MN, and the proportions of sensitive cases, for normals and for the various subgroups of patients (see also
Figures 1 and 3) 
Assay Sensitive Fishers’ Exact P Mean (SD) Mann–Whitney P
n sens (n) % 95% CI vs Normals vs Post vs Normals vs Post 
G2 Normals 27 4 15 4–34 * – 117.7 (14.5) 
All cancer 42 13 31 18–47 0.16 – 122.4 (17.9) 0.46 – 
Pre-therapy 16 2 13 2–38 1.0 0.067 117.3 (14.4) 0.77 0.13 
Post-therapy 20 9 45 23–68 0.045 * 127.0 (19.7) 0.16 *
HR 6 2 33 4–78 0.30 1.0 121.3 (19.4) 0.80 0.74 
G0 Normals 31 3 10 2–26 * – 50.6 (5.8) * – 
All cancer 49 17 35 22–50 0.016 – 55.5 (10.2) 0.056 – 
Pre-therapy 22 9 41 21–64 0.017 0.35 55.8 (11.8) 0.26 0.94 
Post-therapy 23 6 26 10–48 0.15 * 54.1 (8.4) 0.14 *
HR 4 2 50 7–93 0.089 0.56 62.0 (9.8) 0.011 0.13 
*Reference group 15% (4 of 27), not 10%, sensitive normals because the G2 score for
several individuals fell exactly on the cutoff value. For all 42
patients, the proportion of sensitive cases was 31% (13 of 42) but
this was not significantly higher (P = 0.16) than the 15% of sensitive
normals. Of the various patient subgroups, only the post-therapy
group had a sensitive proportion (45%, 9 of 20) that was signifi-
cantly higher than normals (P = 0.045). This proportion of sensi-
tive post-therapy patients was higher than that for pre-therapy
cases (13%, 2 of 16), but the difference did not quite reach statist-
ical significance (P = 0.067). 
There was no indication of any influence of age on radiosensit-
ivity for normal donors (r = 0.002, P = 0.99, Figure 2), but for
patients there was an inverse correlation with age at diagnosis 
(r = 0.32, P = 0.038, Figure 2). It should be pointed out that the
average age of the patients was greater than that of the normals
(Table 1). To further investigate the influence of age on sensitivity in
the assay we have stratified the patients into early (≤ 45 years) and
normal (> 45) onset cases. The mean induced G2 yield of early-onset
cases (127.2 ± 18.6, Table 3) was greater than that of young (< 45
years) normals (112.9 ± 13.5, P = 0.12) and when the difference
between patients and normals was expressed in terms of the propor-
tion of sensitive cases, the difference was statistically significant
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Figure 1 Radiation-induced G2 aberration yields in normals and in the
various subgroups of patients (see also Table 2). The cutoff used to define
the sensitive population is indicated by the solid vertical line, and the mean
aberration yields of each group are shown as broken vertical lines 
Figure 2 The relationship between induced G2 aberration yields and age at
diagnosis (patients = closed symbols) or at the time of testing (normals =
open symbols). See also Table 3. The vertical and horizontal lines indicate
the cutoff values used to define sensitivity in the two assays 
Table 3 Yields of induced G2 aberrations or MN in donors who were above or below the age of 45 years at the time of diagnosis (patients) or testing (normals)
(see also Figures 2 and 4) 
Assay Sensitive Fishers’ Exact P Mean (SD) Mann–Whitney P
n sens (n) % vs Age-matched vs All Early   vs Age- vs All  Early 
normals normals vs matched normals vs Late
Late normals
G2 All Normals 27 4 15 * – 117.7 (14.5) * – 
Early-onset 
Normals 10 0 0 * – * 112.9 (13.5) * – *
Cancer 13 5 38 0.046 0.12 * 127.2 (18.6) 0.12 0.23 *
Late-onset 
Normal 17 4 24 * – 0.26 120.4 (14.7) * – 0.14 
Cancer 29 8 28 1.0 0.33 0.50 120.3 (17.5) 0.69 0.77 0.24 
G0 All Normals 31 3 10 * – 50.6 (5.8) * – 
Early-onset 
Normals 11 1 9 * – * 50.0 (6.1) * – *
Cancer 13 7 54 0.033 0.003 * 59.1 (9.7) 0.026 0.008 *
Late-onset 
Normal 20 2 10 * – 1.0 51.0 (5.7) * – 0.82 
Cancer 36 10 28 0.18 0.072 0.17 54.2 (10.2) 0.38 0.26 0.15 
*Reference groups 
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(38% sensitive patients, 0% sensitive normals, P = 0.046). On the
other hand, mean yields and sensitive proportions were very similar
for patients and normals above the age of 45 years (Table 3). There
was a wide range in smoking and alcohol consumption in both
groups, the mean consumption being higher in the older patients, the
difference reaching statistical significance for smoking but not for
alcohol use (Table 4). There was no significant correlation between
the induced G2 yield and smoking or alcohol consumption. 
There was no influence of gender on either spontaneous or
induced aberration frequencies. 
The MN assay 
The spontaneous MN yield in the patients was not significantly
different from the level of 3.5 ± 2.6 in normals. 
Assay error for induced MN yields, estimated from repeat tests
on six normal donors (three tested twice and three tested three
times) was 6.2%, less than our previous estimate of 13% from
repeat tests on 14 normals (Scott et al, 1999). 
The mean yield of induced MN for all 49 patients (55.6 ±5.8 per
100 cells) was higher than that of the 31 normals (50.6 ± 10.2), on
the borderline of significance (P = 0.056, Table 2). When the
patients were stratified into their various subgroups (Table 2,
Figure 3) mean yields were higher than normals but the level of
statistical significance was less, because of the relatively small
numbers of patients in each subgroup, except for the four HR
patients whose mean yield (62.0 ± 9.8) was significantly above
the normals (P = 0.011). However, the more appropriate group to
compare with the HR cases are the post-therapy patients with a
normal response to therapy. The yield in HR patients was not
significantly higher than that in these normal responders
(54.1 ± 8.4). The response of pre- and post-therapy patients was not
significantly different. The range of values for patients was greater
than that of normals (Figure 3). 
Using the 90th percentile of healthy donors to distinguish sen-
sitive from normal responses gave a cutoff value of 60 MN per 100
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Figure 3 Radiation-induced MN yields in normals and in the various
subgroups of patients (see also Table 2). The cutoff used to define the
sensitive population is indicated by the solid vertical line, and the mean
aberration yields of each group are shown as broken vertical lines 
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Figure 4 The relationship between induced MN yields and age at diagnosis
(patients = closed symbols) or at the time of testing (normals = open
symbols) see also Table 3. The vertical and horizontal lines indicate the
cutoff values used to define sensitivity in the two assays 
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Figure 5 Radiation-induced MN yields and G2 aberrations for the same 64
donors, using the same blood sample for both assays (see also Table 4).
Closed symbols are patients and open symbols are normals. The vertical and
horizontal lines indicate the cutoff values between normal and sensitive
responses in the G0 and G2 assays respectively 
Table 4 Smoking and alcohol consumption in early- or normal-onset
patients tested with the G2 or G0 assays. Not all patients volunteered this
information and the numbers of responses is indicated 
Series Smoking Alcohol 
Mean pack-years Mean units per week 
(SD) (SD) 
G2 Early-onset (≤ 45) 10.4 (9.9) n = 12 7.8 (9.7) n = 4 
Late-onset (> 45) 26.6 (19.9) n = 19 24.5 (24.4) n = 17 
Mann–Whitney P 0.014 0.12 
G0 Early-onset (≤ 45) 11.3 (11.3) n = 12 20.2 (29.1) n = 5 
Late-onset (> 45) 26.2 (18.6) n = 25 21.9 (21.2) n = 23 
Mann–Whitney P 0.016 0.45 Chromosomal radiosensitivity in head and neck cancer patients 781
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cells (Figure 3). The proportion of all patients above this cutoff
value was 35%, which was significantly higher (P = 0.016) than
the 10% value for normals. Each of the patient subgroups had
sensitive proportions above the normals, significantly so for the
pre-therapy group (P = 0.017). 
There was no significant influence of age on the response of
normals (r = 0.22, P = 0.23, Figure 4) but, as with the G2 assay,
there was a significant inverse correlation for patients (r = 0.30,
P = 0.035, Figure 4). Again as with the G2 assay, the mean MN
yield in patients under 45 years at diagnosis (59.1 ± 9.7) was
higher (P = 0.026) than that of the normals of < 45 years
(50.0 ± 6.1, P = 0.026), whereas there was no significant differ-
ence between patients and normals of > 45 years (P = 0.38, Table
3). Similarly, the proportion of sensitive young patients (54%, 7 of
13) was significantly higher than that of young normals (9%, 1 of
11, P = 0.003), whereas the difference in the sensitive proportions
of older patients and normals did not reach statistical significance
(P = 0.18). Smoking and alcohol consumption were, on average,
higher in the older patients, significantly so for smoking (Table 4).
However, there were no significant correlations between MN
yields and smoking or alcohol consumption. 
There was no difference in spontaneous or induced yields of
MN between males and females. 
Both assays 
A total of 64 individuals were tested with both assays on the same
blood sample. These comprised 25 normals and 39 patients (16
pre-therapy, 19 post-therapy and four HR cases). There was no
significant correlation between the results of the two assays
(r = 0.05, P = 0.81 for normals, r = 0.40, P = 0.13 for patients, see
Figure 5). The proportion of individuals who were sensitive in
both assays (5% of those tested, Figure 5) was very close to that
predicted if the results of both assays are completely uncorrelated
(6%). This was also true for the various subgroups of donors. 
DISCUSSION 
We have previously argued that enhanced chromosomal radiosens-
itivity may be a marker for low-penetrance predisposition to breast
cancer. We have now applied both the G2 and G0 micronucleus
assays to patients with head and neck cancers for which there is
epidemiological evidence of inherited risk in spite of a strong
environmental influence, particularly through tobacco and alcohol
useage (Morita et al, 1994; Copper et al, 1995; Foulkes et al,
1995). 
The G2 assay 
With the G2 assay, although the mean yield of aberrations and the
proportion of sensitive cases was higher for all of the patient
groups compared with the normals, this increase was not statistic-
ally significant (Table 2). However, when patients were stratified
on the basis of age of onset of disease, early-onset cases (<45
years) were significantly more sensitive than normals in this age
group, whereas later-onset cases (> 45 years) were of very similar
sensitivity to normals of corresponding age (Table 3). 
Also, there was a significant negative correlation between aber-
ration yields and age for patients but not for normals. If G2 chromo-
somal radiosensitivity is indicative of genetic predisposition to
head and neck cancers, as we have suggested for breast cancer, the
above results would indicate that for early-onset cases there is a
genetic contribution to risk, but not so for normal-onset cases. For
the latter, environmental influences may predominate. It should be
noted that smoking and alcohol consumption were higher in the
latter group (Table 4). There is some evidence that head and neck
cancers in young adults may be clinically different from those in
older patients, tending to be more anaplastic and consequently
more aggressive (Son and Kapp, 1985) although this difference
has not been seen in all studies (Von Doersten et al, 1995). 
These results for head and neck cancer patients differ from those
for breast cancer cases in that there was no age-dependence for G2
sensitivity in the latter group (Scott et al, 1999). The proportion of
young head and neck cases that were sensitive (38%) was similar
to that for all breast cancer patients (42%), but since early-onset
head and neck cancers represent <5% of all cases (references in
Son and Kapp, 1985), our results with the G2 assay would suggest
a considerably lower genetic component in the overall risk of head
and neck cancer than for breast cancer. Terzoudi et al (2000)
recently reported that the mean G2 sensitivity of 185 patients with
various cancers was significantly higher than that of 25 normals.
Among the patients were 20 cases of laryngeal cancer whose G2
scores were higher than those of the normals, although the statis-
tical significance of this increase was not given and the ages of the
patients were not specified. 
Enhanced sensitivity of G2 lymphocytes of head and neck
cancer patients to the chromosome-damaging agent, bleomycin,
has been reported in several studies (references in Cloos et al,
1996). In a large case-control study of risk-factors for head and
neck cancer, in which age, history of tobacco and alcohol usage,
and bleomycin G2 sensitivity were recorded, it was shown that the
latter parameter is a biomarker of cancer susceptibility, since it
modulates the risk from carcinogen exposure (Cloos et al, 1996). It
has also been shown that, as in the case of G2 X-ray sensitivity
(Roberts et al, 1999), there is a strong inherited component in G2
bleomycin sensitivity (Cloos et al, 1999). However, G2 response to
X-rays cannot simply be regarded as a surrogate for response to
bleomycin because, although breast cancer cases show enhanced
X-ray sensitivity, they exhibit a normal bleomycin response (Hsu
et al, 1989). Also, unlike our present observations on head and
neck cancer patients, Cloos et al (1996) found a significant posi-
tive correlation between age and G2 bleomycin sensitivity in 313
such patients. 
The fact that we were unable to distinguish between patients
who had shown late HR reactions or normal responses to radio-
therapy with the G2 assay agrees with our studies on breast cancer
patients, where this assay was only able to distinguish patients
with acute HR reactions (Barber et al, 2000). In the present study
and that on breast cancer patients there was an indication that non-
HR patients tested post-therapy were more sensitive than pre-
therapy patients, but in neither case was this difference statistically
significant. The possibility that radiotherapy may alter the res-
ponse of lymphocytes in the G2 assay requires further investigation
on the same group of patients tested before and after treatment. 
The micronucleus assay 
As we found in our studies of breast cancer patients (Scott et al,
1999), in the present investigations we found no significant
correlation between the results of the G2 and G0 assays. This
suggests that different mechanisms are responsible for enhanced
sensitivity in the two tests and that these assays are independent782 R Papworth et al 
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markers of predisposition to both breast and head and neck
cancers. 
Using either the mean MN yields or the proportion of sensitive
cases, there was better discrimination between patients and
normals with this assay than with the G2 assay (Table 2). However,
as with the G2 assay, this difference was seen mainly in early-onset
patients where 54% were sensitive compared with 9% normals
(Table 3). The inverse correlation between MN yields and patient
age differs from that for breast cancer patients, where no signifi-
cant trend was seen (Scott et al, 1999). Further quantitative
comparisons with the MN and breast cancer data are probably of
limited value because of differences between the assays used in the
two studies (Materials and methods). 
Rached et al (1998) showed that the average sensitivity of 15
cancer patients was greater than that of 15 normals, using a
lymphocyte MN assay. The patients included eight cases of head
and neck cancer but their individual MN scores and ages were not
given. 
There was a suggestion of enhanced mean sensitivity of the four
patients who had shown adverse late reactions to radiotherapy,
compared with 23 normally-reacting cases, but the difference was
not significant. In a study of a larger number of breast cancer
patients we obtained better discrimination between severe late
reactors and normal reactors but, again, there was a complete
overlap of values for the two groups, which obviously limits the
value of the assay for predictive purposes (Barber et al, 2000). 
Our main finding is that both assays are able to identify chromo-
somally radiosensitive groups of early-onset patients who may be
genetically predisposed to head and neck cancer, each assay
detecting a different subgroup of these patients.
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